Intech Investment Management LLC Has $735,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Intech Investment Management LLC grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 80.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 97,793 shares of the biotechnology company's stock after buying an additional 43,556 shares during the quarter. Intech Investment Management LLC's holdings in BioCryst Pharmaceuticals were worth $735,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in BCRX. Cibc World Markets Corp acquired a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $145,000. May Barnhard Investments LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth $226,000. Swiss National Bank boosted its stake in BioCryst Pharmaceuticals by 6.2% in the fourth quarter. Swiss National Bank now owns 386,568 shares of the biotechnology company's stock valued at $2,907,000 after buying an additional 22,600 shares in the last quarter. Jupiter Asset Management Ltd. grew its position in BioCryst Pharmaceuticals by 10.1% in the fourth quarter. Jupiter Asset Management Ltd. now owns 1,177,929 shares of the biotechnology company's stock valued at $8,858,000 after acquiring an additional 108,030 shares during the last quarter. Finally, Bender Robert & Associates acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $178,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX traded up $0.03 during trading hours on Thursday, hitting $7.83. 1,289,217 shares of the stock were exchanged, compared to its average volume of 2,749,287. The firm has a market capitalization of $1.64 billion, a P/E ratio of -12.84 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The business has a 50-day moving average of $8.15 and a 200-day moving average of $7.82.

Remove Ads

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. The company's quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.28 earnings per share. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BCRX. Wedbush assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Needham & Company LLC lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, JMP Securities reiterated a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.